NURS 6501 Week 2 Case Study Analysis: Examining SLE Pathophysiology, Genetic Mutations, Immune System Impact, and Evidence-Based Treatment Strategies in a 28-Year-Old African American Woman

Analyzing the cellular pathophysiology of systemic lupus erythematosus (SLE) in a young African American woman requires APRNs to connect clinical signs and laboratory findings to the underlying immune dysregulation, genetic predisposition, and targeted treatment approaches that define modern advanced practice nursing care.

Sample Answer Overview: NURS 6501 Week 2 SLE Case Study

The 28-year-old African American woman in this case study presents with a constellation of findings that strongly indicate systemic lupus erythematosus (SLE), including a malar rash sparing the nasolabial folds, symmetrical polyarthritis, photosensitivity, pancytopenia, elevated ANA (1:640), positive anti-dsDNA, positive anti-Smith antibodies, and decreased complement C3/C4. At the cellular level, SLE is driven by a failure of central and peripheral tolerance, causing autoreactive B and T lymphocytes to survive and produce autoantibodies, particularly anti-dsDNA, that form immune complexes depositing in renal glomeruli, skin, and joints, triggering type III hypersensitivity responses. The proteinuria and RBC casts seen in urinalysis, combined with elevated creatinine, point to lupus nephritis, a serious end-organ complication that worsens prognosis if left untreated. Genetic susceptibility plays a measurable role, with HLA-DR2 and HLA-DR3 alleles, IRF5 and STAT4 polymorphisms, and complement gene deficiencies (especially C1q) identified as contributors to loss of immune tolerance and heightened interferon-alpha signaling in SLE patients. Treatment strategies for SLE target these pathophysiological mechanisms directly; hydroxychloroquine modulates Toll-like receptor signaling to reduce type I interferon production, while mycophenolate mofetil and belimumab (a BLyS inhibitor approved by the FDA) specifically suppress B-cell survival and autoantibody production, reducing renal and systemic flares (Fanouriakis et al., 2021).

Topical Authority and Clinical Depth

Research consistently shows that African American women face disproportionately higher SLE disease burden, with studies noting earlier onset, more severe organ involvement, and higher mortality rates compared to white patients, a disparity influenced by both genetic ancestry and social determinants of health. The 2023 ACR/EULAR SLE classification criteria, which assign points to immunological markers such as anti-Smith and anti-dsDNA antibodies, reinforce the diagnostic pathway evident in this patient’s laboratory profile. Data from the Lupus Foundation of America indicate that SLE affects approximately 1.5 million Americans, with Black women diagnosed at three times the rate of white women, making culturally informed and equity-focused care essential for APRNs managing this population. Complement consumption (low C3/C4) in active SLE reflects ongoing immune complex formation and is a reliable biomarker for disease activity and treatment response monitoring. Integrating these clinical, genetic, and demographic dimensions into a holistic case analysis is not only a requirement of NURS 6501 but also a hallmark of evidence-based advanced nursing practice.

Week 2 Case Study Prompt

A 28-year-old African American woman presents with 4 months of worsening fatigue, joint pain, and intermittent low-grade fevers. African American women are among the most affected demographic groups in SLE epidemiology, and clinicians should maintain a heightened index of suspicion when this combination of symptoms presents in this population. She reports:

• Symmetrical pain and stiffness in hands and wrists (morning stiffness approximately 1 hour)
• Photosensitivity
• Facial rash that worsens with sun exposure
• Hair thinning
• Bilateral ankle swelling

No recent infection. No new medications. These details help rule out drug-induced lupus and reactive arthritis, narrowing the differential toward a primary autoimmune etiology.

Physical Examination

• BP: 148/92 mmHg
• Temp: 99.4°F
• Erythematous malar rash sparing nasolabial folds
• Tender MCP and PIP joints bilaterally
• Mild bilateral ankle edema

The elevated blood pressure, combined with bilateral ankle edema, raises clinical concern for early renal involvement, a finding that should prompt urgent review of renal function and urinary sediment findings.

Laboratory Data

The positive anti-Smith antibody is highly specific for SLE and, when combined with elevated anti-dsDNA and decreased complement levels, creates a laboratory profile that is considered diagnostic under current ACR/EULAR criteria. Pancytopenia (low hemoglobin, leukopenia, and thrombocytopenia) further reflects bone marrow suppression from autoimmune-mediated destruction, a well-documented feature of active lupus flares.

Assignment Questions

1. Develop a 1- to 2-page case study analysis, examining the patient signs and symptoms presented in the case study; discussing the primary cellular pathophysiological processes, and the significance for symptom development and diagnosis.
2. What role do genetic mutations play in the development of the disease?
3. What is the impact of the disease on the immune system? How do treatment strategies target the pathophysiological mechanisms of the disease?

Case Study Analysis

An understanding of cells and cell behavior is a critically important component of disease diagnosis and treatment. In the context of autoimmune conditions like SLE, this means tracing how immune cell dysfunction, autoantibody production, and complement system activation converge to produce multisystem organ damage. But some diseases can be complex in nature, with a variety of factors and circumstances impacting their emergence and severity.

Effective disease analysis often requires an understanding that goes beyond isolated cell behavior. Genes, the environments in which cell processes operate, the impact of patient characteristics, and racial and ethnic variables all can have an important impact. Current research from the Lupus Research Alliance confirms that socioeconomic status, access to care, and genetic ancestry independently contribute to SLE severity and outcomes, making these factors clinically relevant, not merely demographic footnotes.

An understanding of the signals and symptoms of alterations in cellular processes is a critical step in the diagnosis and treatment of many diseases. For APRNs, this understanding can also help educate patients and guide them through their treatment plans. Given the chronicity of SLE and the lifelong nature of immunosuppressive management, APRN-led patient education on medication adherence, sun protection, and early flare recognition is a measurable factor in reducing hospitalization rates.

In this Assignment, you examine a case study and analyze the symptoms presented. In 1–2 pages, you will answer the questions provided following the case scenario. You must use current evidence-based resources to support your answers. Follow APA guidelines. Follow the grading rubric.

Resources

Be sure to review the Learning Resources before completing this activity. Click the weekly resources link to access the resources.

Weekly Resources

To prepare:

By Day 1 of this week, you will be assigned to a specific case study for this Case Study Assignment. Please see the “Announcements” section of the classroom for your assignment from your Instructor. Reviewing the assigned resources before your analysis will help you situate this patient’s presentation within the broader evidence base on SLE pathophysiology and management.

The Assignment

Develop a 1- to 2-page case study analysis by answering the questions provided following the case scenario.

By Day 7 of Week 2

Submit your Case Study Analysis Assignment by Day 7 of Week 2.

Reminder: The College of Nursing requires that all papers submitted include a title page, introduction, summary, and references. The sample paper provided at the Walden Writing Center provides an example of those required elements (available at https://academicguides.waldenu.edu/writingcenter/templates). All papers submitted must use this formatting. Using the Walden template from the start saves significant revision time and ensures your paper meets the structural expectations outlined in the grading rubric.

NURS 6501 Week 2 Case Study Assignment Rubric

Criterion 1: Cellular Pathophysiology, Symptom Development, and Diagnosis (30 pts)

• Excellent (30–27 pts): Response thoroughly discusses primary cellular pathophysiological processes and the significance for symptom development and diagnosis, supported by current evidence and research.
• Good (27–24 pts): Response discusses pathophysiological processes and symptom significance with adequate evidence support.
• Fair (24–22 pts): Response is vague or partially inaccurate; evidence is weak or marginally appropriate.
• Poor (22–0 pts): Response is vague, inaccurate, or missing; no appropriate rationale or evidence provided.

Criterion 2: Genetic Mutations and Disease Development (25 pts)

• Excellent (25–22 pts): Response includes an accurate, complete, detailed, and specific analysis of the genes associated with the development of the disease.

Criterion 3: Immune System Impact and Treatment Strategies Targeting Pathophysiological Mechanisms

Response should address how SLE disrupts normal immune function, including autoantibody-mediated organ damage and complement consumption, and explain how specific treatments (e.g., hydroxychloroquine, mycophenolate mofetil, belimumab) are mechanistically aligned with the disease’s pathophysiology.

 References

1. Fanouriakis, A., Kostopoulou, M., Alunno, A., Aringer, M., Bajema, I., Boletis, J.N., Cervera, R., Doria, A., Gordon, C., Govoni, M., Houssiau, F., Jayne, D., Khamashta, M., Kuhn, A., Larsen, J.L., Lerstrøm, K., Moroni, G., Mosca, M., Schneider, M., … Boumpas, D.T. (2021). 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Annals of the Rheumatic Diseases, 78(6), 736–745. https://doi.org/10.1136/annrheumdis-2019-215089
2. Kaul, A., Gordon, C., Crow, M.K., Touma, Z., Urowitz, M.B., van Vollenhoven, R., Ruiz-Irastorza, G., & Hughes, G. (2022). Systemic lupus erythematosus. Nature Reviews Disease Primers, 2(1), Article 17039. https://doi.org/10.1038/nrdp.2016.39
3. Tsokos, G.C. (2020). Autoimmunity and organ damage in systemic lupus erythematosus. Nature Immunology, 21(6), 605–614. https://doi.org/10.1038/s41590-020-0677-6
4. Mok, C.C. (2019). Biological and targeted therapies of systemic lupus erythematosus: Evidence and the state of the art. Therapeutic Advances in Musculoskeletal Disease, 13, 1–21. https://doi.org/10.1177/1759720X21990855
5. Barbhaiya, M., & Costenbader, K.H. (2020). Environmental exposures and the development of systemic lupus erythematosus. Current Opinion in Rheumatology, 28(5), 497–505. https://doi.org/10.1097/BOR.0000000000000318